Fig. 1: Relationship between Oncotype DX recurrence score and pCR to neoadjuvant chemotherapy in HR-positive/HER2-negative breast cancer patients. | npj Breast Cancer

Fig. 1: Relationship between Oncotype DX recurrence score and pCR to neoadjuvant chemotherapy in HR-positive/HER2-negative breast cancer patients.

From: Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients

Fig. 1

a Boxplot of Oncotype DX recurrence score by pCR. The horizontal lines in the box denote the first quartile, median, and third quartile. The boundaries of the whiskers are based on the 1.5 interquartile values. b Estimated rate of pCR using restricted cubic spline logistic regression. The two black dash lines represent the 95% confidence interval of the estimated pCR rate. Abbreviations: pCR pathologic complete response, HR hormone receptor, HER2 human epidermal growth factor receptor 2, CI confidence interval.

Back to article page